Business Wire

ADVA

21.10.2021 07:02:07 CEST | Business Wire | Press release

Share
ADVA manages supply constraints and grows revenues and profitability in Q3 2021

ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported its financial results for Q3 2021 ended on September 30, 2021. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005879/en/

Q3 2021 financial summary1

(in thousands of EUR)

 

Q3

 

Q3

 

Change

 

Q2

 

Change

 

 

2021

 

2020

 

 

 

2021

 

 

 

Revenues

 

151,777

 

146,676

 

3.5%

 

149,354

 

1.6%

Pro forma gross profit

 

52,153

 

51,930

 

0.4%

 

57,274

 

-8.9%

in % of revenues

 

34.4%

 

35.4%

 

-1.0pp

 

38.3%

 

-3.9pp

Pro forma operating income

 

13,012

 

11,053

 

17.7%

 

14,415

 

-9.7%

in % of revenues

 

8.6%

 

7.5%

 

1.1pp

 

9.7%

 

-1.1pp

Operating income (loss)2

 

9,496

 

9,768

 

-2.8%

 

13,036

 

-27.2%

Net income

 

18,478

 

6,671

 

177.0%

 

12,001

 

54.0%

 

(in thousands of EUR)

 

Sep. 30

2021

 

Sep. 30

2020

 

Change

 

Jun. 30

2021

 

Change

Cash and cash equivalents

 

100,513

 

68,293

 

47.2%

 

85,023

 

18.2%

Net cash (+) / Net debt (-)

 

20,610

 

-35,009

 

n.a.

 

3,876

 

431.7%

Net working capital

 

130,794

 

124,043

 

5.4%

 

132,767

 

-1.5%

1 Potential difference due to rounding
2 Q3 2021 including EUR 2.1 million extraordinary expenses

Q3 2021 IFRS financial results
Revenues in Q3 2021 reached EUR 151.8 million, up by 1.6% from EUR 149.4 million in Q2 2021, also up by 3.5% compared to EUR 146.7 million in Q3 2020. The increase in revenues is predominantly driven by a growth in demand from communication service providers (CSPs).

Pro forma gross profit in Q3 2021 decreased by 8.9%, reaching EUR 52.2 million (34.4% of revenues) compared to EUR 57.3 million (38.3% of revenues) in Q2 2021 and increased by 0.4% compared to EUR 51.9 million (35.4% of revenues) reported in Q3 2020. The reduction in gross profit compared to the previous quarter is mainly attributable to the semiconductor crisis, which led to increased purchasing costs.

Pro forma operating income for Q3 2021 was EUR 13.0 million (8.6% of revenues) and decreased by 9.7% compared to EUR 14.4 million (9.7% of revenues) reported in Q2 2021. Compared to Q3 2020, pro forma operating income improved substantially by 17.7% from EUR 11.1 million (7.5% of revenues).

Operating income for Q3 2021 of EUR 9.5 million decreased substantially by 27.2% from EUR 13.0 million reported for Q2 2021 and slightly decreased by 2.8% from EUR 9.8 million in Q3 2020. Operating income for Q3 2021 was impacted by extraordinary expenses in connection with the announced merger with ADTRAN amounting to EUR 2.1 million.

Net income reached EUR 18.5 million in Q3 2021, substantially up by 54.0% from EUR 12.0 million in Q2 2021, and significantly up by 177.0% from EUR 6.7 million in Q3 2020. The significant increase in net income is mainly due to a tax benefit of EUR 8.8 million resulting from increased deferred tax assets.

The company’s cash and cash equivalents totaled EUR 100.5 million, representing an increase of EUR 15.5 million compared to EUR 85.0 million at the end of Q2 2021. Year-over-year cash and cash equivalents substantially increased by EUR 32.2 million from EUR 68.3 million at the end of Q3 2020.

Net cash at the end of Q3 2021 stood at EUR 20.6 million compared to a net cash position of EUR 3.9 million at the end of Q2 2021 or a net debt position of EUR 35.0 million at the end of Q3 2020.

Net working capital at quarter-end was EUR 130.8 million and decreased by EUR 2.0 million compared to EUR 132.8 million at the end of Q2 2021 and increased by EUR 6.8 million compared to EUR 124.0 million at the end of Q3 2020.

Management commentary
“Customer demand for our solutions remains strong and we’re fighting hard to overcome the current supply chain challenges,” said Brian Protiva, CEO, ADVA. “We’re also looking forward to the planned business combination with ADTRAN. Our industry is in the early stages of an unprecedented investment cycle in fiber expansion propelled by the goal of delivering high-speed connectivity to all homes, businesses and the future 5G infrastructure. This expansion of the digital infrastructure requires new, innovative solutions and drives convergence at the network edge. Together with ADTRAN, we’re creating a market and innovation leader in this space that offers the industry’s most comprehensive and unique portfolio of solutions based on openness, scalability, security and software-controlled automation.”

“In view of the global semiconductor crisis, the third quarter was definitely challenging. Nevertheless, we managed to grow and generate solid margins. In addition, we were able to generate cash, and with more than EUR 100 million cash and a net cash position of around EUR 21 million, we further improved our level of financial flexibility,” said Uli Dopfer, CFO, ADVA. “The semiconductor crisis will last longer than we originally assumed, and the coming weeks and months will certainly be demanding again. Nevertheless, we are confident that with these strong numbers and order books at a record level, we will be able to overcome these supply challenges and close the year with good results within our outlook.”

Financial outlook 2021
For the fiscal year 2021, ADVA still expects revenues to be in the range of EUR 580 million and EUR 610 million and a pro forma operating income of between 7.0% and 10.0% of revenues.

The company will publish its financial results for Q4 and the full fiscal year 2021 on February 24, 2022.

Conference call details
ADVA will hold a conference call for analysts and investors today, October 21, 2021, to discuss the Q3 2021 results. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.

A corresponding presentation is available on ADVA’s website:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls

The complete quarterly statement 9M 2021 (January – September) is available as a PDF:
https://www.adva.com/en/about-us/investors/financial-results/financial-statements

A replay of the call will be available here:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls

Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.

Use of pro forma financial information
ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to M&A and restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye